Silo Pharma Collaborates With Medspray Pharma For Intranasal Technology For Stress Disorder Candidate
Portfolio Pulse from Vandana Singh
Silo Pharma Inc (NASDAQ:SILO) has entered into an exclusive license agreement with Medspray Pharma BV for its soft mist nasal spray technology, which will be used for Silo's intranasal drug SPC-15, aimed at treating PTSD, anxiety, Alzheimer's, and anorexia. The technology promises better nasal deposition and reduced systemic absorption, enhancing patient safety and therapeutic delivery. SPC-15, a 5-HT4 receptor agonist, could benefit from the FDA's 505(b)(2) pathway if successful in trials. Silo Pharma is conducting preclinical studies with Columbia University.
November 21, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma has licensed Medspray's nasal spray technology for its SPC-15 drug, potentially improving treatment for PTSD and other disorders. The partnership could enhance Silo's product pipeline and market position if SPC-15 proves successful.
The exclusive license agreement with Medspray for the nasal spray technology is a significant development for Silo Pharma, as it could improve the delivery and efficacy of their SPC-15 drug. This partnership is likely to be viewed positively by investors, as it represents progress in the drug's development pathway and could lead to a competitive advantage in the market for PTSD and anxiety treatments. The potential for streamlined FDA approval through the 505(b)(2) pathway also adds to the positive outlook. However, the confidence score is not at the maximum due to the inherent risks and uncertainties in drug development.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100